(Licensed China/Pacific Rim rights to Huadong Pharmaceuticals)


Glucagon-like peptide-1 (GLP-1) is a member of the incretin family of neuroendocrine peptide hormones secreted from L-cells of the intestine in response to food ingestion. GLP-1 has multiple metabolic effects that are attractive for an anti-diabetic agent.  A key function of GLP-1 is to activate its receptor, GLP-1R, on the pancreatic β-cell to enhance glucose-dependent insulin secretion.  Additional positive metabolic benefits of GLP-1 include suppression of excessive glucagon production, decreased food intake, delayed gastric emptying and improvement of β-cell mass and function. Unfortunately, the rapid proteolysis of GLP-1 in blood limits its use as a therapeutic agent.

There are currently several marketed GLP-1 mimetics (biologic agents).  These agents have demonstrated notable glucose lowering in addition to weight loss.  However, their widespread use is hindered by the route of administration (injection), and by the high incidence of gastrointestinal side effects (nausea and vomiting).

TTP273 has been identified using TTP Translational Technology®, as an orally bioavailable, potent, non-peptide agonist of GLP-1R for the treatment of type 2 diabetes. This molecule is the second generation from our path-finder molecule TTP054, and it is anticipated to provide excellent glycemic control and an attractive safety profile for the treatment of type 2 diabetes.   

The program candidate, TTP273, has completed a 3 month phase 2 study in patients with T2DM where it demonstrated a statistically significant reduction in HbA1c. TTP273 was well-tolerated, with negligible incidences of nausea and vomiting across all arms of the study. Trends towards weight loss were also observed.

Presentations and Posters

Links to the following publications and presentations, which are located on outside websites, are provided for informational purposes only and do not constitute the opinions or views of vTv Therapeutics